PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Clinical trials for PRIMARY IMMUNODEFICIENCY DISEASES (PID) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNODEFICIENCY DISEASES (PID) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot for immune deficiency shows promise in early trial
Disease control CompletedThis study tested a new medicine called TAK-881 in 65 people with primary immunodeficiency diseases (PIDD), which make it hard for the body to fight infections. The goal was to see how well the body processes TAK-881 compared to an existing treatment (HYQVIA) and to check its saf…
Matched conditions: PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Phase: PHASE2, PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 10:09 UTC
-
New drug TAK-771 tested for long-term safety in immune disorder patients
Disease control CompletedThis study looked at the long-term safety of a drug called TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID), a condition where the immune system is weak. Participants who completed an earlier study received TAK-771 injections for up to 3 years. The main…
Matched conditions: PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 14, 2026 12:02 UTC